Matthew Kiernan, MBBS, PhD, DSc, FRACP, FAHMS, University of Sydney, Sydney, Australia, discusses the interim data from the Phase II RESCUE-ALS trial (NCT04098406) open-label extension of CNM-Au8, an investigational oral suspension of gold nanocrystals in patients with amyotrophic lateral sclerosis (ALS). The Phase II RESCUE-ALS study showed benefits and improvement in patients treated with CNM-Au8 compared with placebo. The open-label extension data suggest that those treated with CNM-Au8 experienced a survival benefit. Additionally, there were fewer events for patients, fewer complications, and fewer deaths on the active compound. This interview took place at the American Academy of Neurology 2022 Congress in Seattle, WA.